Neurocrine Biosciences filed an amendment to its Form 8-K to include audited financial statements for acquired entity Soleno Therapeutics and unaudited pro forma combined income statements. The filing confirms the completion of the acquisition on May 18, 2026, at a cash price of $53.00 per share. Neurocrine also entered into a five-year, $1.0 billion senior secured revolving credit facility with JPMorgan Chase Bank to fund working capital needs post-acquisition. The company drew and subsequently repaid $600 million under this facility by June 30, 2026. Pro forma results indicate combined revenues of $1.9 billion for the six months ended June 30, 2026, and $3.1 billion for the year ended December 31, 2025. Neurocrine Biosciences operates in the biotechnology industry, developing and commercializing innovative medicines for central nervous system disorders.

Neurocrine Biosciences reported second-quarter 2026 financial results with total revenues of $959 million, a 39% increase year-over-year from $688 million. GAAP diluted earnings per share were $1.39, compared to $1.06 in the prior year period. The company raised its full-year 2026 INGREZZA net product sales guidance to $2.825–$2.875 billion from a previous range of $2.7–$2.8 billion. Neurocrine completed its acquisition of Soleno Therapeutics in May 2026 for $2.9 billion, adding VYKAT XR to its portfolio, and entered into a $1.0 billion senior secured revolving credit facility. The biopharmaceutical company discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders.